Johnson & Johnson
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Johnson & Johnson is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Johnson & Johnson embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportBoard Bias
Expand Summary
CEO of Johnson & Johnson
Joaquin B. Duato
Summary:
Headquartered in New Brunswick, New Jersey, Johnson & Johnson is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Joaquin B. Duato serves as CEO/President and Chairman, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $135,500 to Republican causes and $165,070 to Democratic causes. Under their tenure, Johnson & Johnson currently holds a 'High Risk' risk rating.
View Full Board Bias ReportPolitical Contributions of Leadership:
$135,500
$165,070
Republican
Democrat
China Risk Database
Expand Summary
Total Estimated Sanctions (3-year Avg.)
$4,189,021,148
Average Annual Revenue
Global
$81,385,000,000
China Revenue
19.10%
$15,544,446,722
Annual Average of Total Assets
Global
$171,742,000,000
China Assets
19.20%
$32,976,528,946
Shareholder Proposals
Expand Summary
| Date | ESG Category | Proponent | Summary of Resolution | Mgmt Rec | Total Vote % in Favor |
|---|---|---|---|---|---|
| 4/25/24 | Social | National Legal and Policy Center | Shareholder Proposal- Gender-Based Compensation Gaps and Associated Risks | Against | 3.86% |
| 4/25/24 | Social | Mercy Investment Services | Impact of Extended Patent Exclusivities on Patient Access | Against | 89.96% |
| 5/31/23 | Social | Jubitz Foundation | Shareholder proposal to discontinue the development of a non-lethal TASER drone system | Against | 0.00% |
| 4/27/23 | Governance | Hal Scott/Doris Behr 2012 Irrevocable Trust | Adopt Federal Securities Laws Mandatory Arbitration Bylaw | against | 0.00% |
| 4/27/23 | Social | Oxfam America, Inc. | Vaccine Pricing Report | Against | 31.30% |
| 4/27/23 | Social | Mercy Investment Services, Inc. | Impact of Extended Patent Exclusivities on Product Access | Against | 14.20% |
| 4/28/22 | Social | Mercy Investment Services | Third Party Racial Equity Audit | Against | 62.64% |
| 4/28/22 | Governance | Vermont Pension Investment Committee | Adopt Policy to Include Legal & Compliance Costs in Incent. Compensation Metrics | Against | 47.71% |
| 4/28/22 | Social | SHARE (Sharehldr Assoc for Research & Educ | Third Party Report on Lobbying Activities Alignment with Public Statements | Against | 43.26% |
| 4/28/22 | Social | Oxfam America, Inc. | Report on Government Financial Support & Access to COVID-19 Vaccines | Against | 33.80% |
| 4/28/22 | Social | Tulipshare Ltd. | Discontinue Global Sales of Baby Powder Containing Talc | Against | 15.63% |
| 4/28/22 | Governance | Myra K. Young | Consider Pay Disparity Between Executives and Other Employees | Against | 10.83% |
| 4/28/22 | Social | Harrington Investments, Inc. | Report on Public Health Costs of Protecting Vaccine Technology | Against | 8.68% |
| 4/28/22 | Social | National Legal and Policy Center | Request for Charitable Donations Disclosure | Against | 4.07% |
| 4/28/22 | Social | National Center for Public Policy Research | Civil Rights, Equity, Diversity & Inclusion Audit | Against | 2.74% |